• Collaboration will leverage Atavistik Bio’s proprietary AMPS™ platform to rapidly identify and validate novel allosteric binders against two undisclosed, Pfizer-designated targets
• Atavistik Bio has rapidly identified novel, functional, allosteric binding pockets across a broad range of intractable target classes
• Collaboration with Pfizer will enable Atavistik Bio to extend the reach of its platform to potentially address a broader range of oncology indications, while simultaneously progressing its internal pipeline of precision oncology small molecule therapies

Atavistik Bio, a biotechnology company committed to discovering the next generation of precision allosteric therapeutics inspired by the body’s natural regulators, today announced that it has entered into a research collaboration with Pfizer to accelerate the discovery of novel precision allosteric therapeutics to address significant unmet medical needs.

Under the terms of the collaboration, Atavistik Bio will leverage its proprietary AMPS™ platform to identify novel allosteric binders against two undisclosed, targets selected by Pfizer. At the completion of the research period, Pfizer will have the option to license the programs. The financial terms of the collaboration are undisclosed.

“Allostery holds the key to targeting disease-causing proteins and delivering highly selective, better tolerated, and more effective therapies. We’re excited to collaborate with Pfizer to harness the tremendous promise of allostery to advance the opportunity for therapeutic innovations for patients in need,” said Bryan Stuart, CEO of Atavistik Bio. “Our internal pipeline has been enabled by our ability to identify novel, functional allosteric binding pockets that allow us to rapidly progress novel chemical matter. We look forward to applying the efficiency and productivity of our platform to our collaboration with Pfizer as we simultaneously advance our internal pipeline of precision oncology small molecule therapies.”